Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
¿Qué tal es el rendimiento del precio de la acción BBNX?
El precio actual de BBNX es de $10.52, ha disminuido un 3.21% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Beta Bionics Inc?
Beta Bionics Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Beta Bionics Inc?
La capitalización bursátil actual de Beta Bionics Inc es $466.8M
¿Es Beta Bionics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 13 analistas han realizado calificaciones de análisis para Beta Bionics Inc, incluyendo 6 fuerte compra, 6 compra, 3 mantener, 0 venta, y 6 fuerte venta